bims-mirpro Biomed News
on MiRNA as biomarker in prostate cancer diagnosis and prognosis
Issue of 2023–06–25
ten papers selected by
Garima Jain, Banaras Hindu University
  1. MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer.
  2. Role of microRNA carried by small extracellular vesicles in urological tumors.
  3. Angiogenesis and prostate cancer: MicroRNAs comes into view.
  4. MicroRNA-425: A Pivotal Regulator Participating in Tumorigenesis of Human Cancers.
  5. Urologic Oncology: Prostate Cancer.
  6. The potential role of miRNAs in the pathogenesis of cardiovascular diseases - A focus on signaling pathways interplay.
  7. The miRNA neuroinflammatory biomarkers in COVID-19 patients with different severity of illness.
  8. Bacterial extracellular vesicles: an emerging avenue to tackle diseases.
  9. The relationship between microRNAs and bladder cancer: are microRNAs useful to predict bladder cancer in suspicious patients?
  10. An Extracellular miRNA-Responsive Artificial Receptor via Dynamic DNA Nano-assembly for Biomarker-Driven Therapy.
  1. Pathol Res Pract. 2023 Jun 13. pii: S0344-0338(23)00318-7. [Epub ahead of print]248 154618
    MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer.
    Alireza Azani, Sima Parvizi Omran, Haniyeh Ghasrsaz, Asra Idani, Mahdis Kadkhodaei Eliaderani, Niloufar Peirovi, Negar Dokhani, Mohamad Hassan Lotfalizadeh, Mohammadhadi Mohammadzadeh Rezaei, Mehrnoosh Shahgholian Ghahfarokhi, Sepideh KarkonShayan, Parisa Najari Hanjani, Zahra Kardaan, Jamshid Gholizadeh Navashenagh, Meysam Yousefi, Mitra Abdolahi, Arash Salmaninejad.
      Globally, prostate cancer (PC) is leading cause of cancer-related mortality in men worldwide. Despite significant advances in the treatment and management of this disease, the cure rates for PC remains low, largely due to late detection. PC detection is mostly reliant on prostate-specific antigen (PSA) and digital rectal examination (DRE); however, due to the low positive predictive value of current diagnostics, there is an urgent need to identify new accurate biomarkers. Recent studies support the biological role of microRNAs (miRNAs) in the initiation and progression of PC, as well as their potential as novel biomarkers for patients' diagnosis, prognosis, and disease relapse. In the advanced stages, cancer-cell-derived small extracellular vesicles (SEVs) may constitute a significant part of circulating vesicles and cause detectable changes in the plasma vesicular miRNA profile. Recent computational model for the identification of miRNA biomarkers discussed. In addition, accumulating evidence indicates that miRNAs can be utilized to target PC cells. In this article, the current understanding of the role of microRNAs and exosomes in the pathogenesis and their significance in PC prognosis, early diagnosis, chemoresistance, and treatment are reviewed.
    Keywords:  Biomarkers; Chemoresistance; Diagnosis; Exosomes; MicroRNAs; Prognosis; Prostate cancer
    DOI:  https://doi.org/10.1016/j.prp.2023.154618
  2. Front Cell Dev Biol. 2023 ;11 1192937
    Role of microRNA carried by small extracellular vesicles in urological tumors.
    Yiping Mao, Mengting Zhang, Lanfeng Wang, Yukang Lu, Xinyi Hu, Zhiping Chen.
      Small extracellular vesicles (sEVs) are minute vesicles secreted by various cells that are capable of transporting cargo, including microRNAs, between donor and recipient cells. MicroRNAs (miRNAs), small non-coding RNAs approximately 22 nucleotides in length, have been implicated in a wide array of biological processes, including those involved in tumorigenesis. Emerging evidence highlights the pivotal role of miRNAs encapsulated in sEVs in both the diagnosis and treatment of urological tumors, with potential implications in epithelial-mesenchymal transition, proliferation, metastasis, angiogenesis, tumor microenvironment and drug resistance. This review provides a brief overview of the biogenesis and functional mechanisms of sEVs and miRNAs, followed by a summarization of recent empirical findings on miRNAs encapsulated in sEVs from three archetypal urologic malignancies: prostate cancer, clear cell renal cell carcinoma, and bladder cancer. We conclude by underscoring the potential of sEV-enclosed miRNAs as both biomarkers and therapeutic targets, with a particular focus on their detection and analysis in biological fluids such as urine, plasma, and serum.
    Keywords:  MicroRNAs; barrett esophagus; diagnosis; small extracelllular vesicles; therapy; urological tumors
    DOI:  https://doi.org/10.3389/fcell.2023.1192937
  3. Pathol Res Pract. 2023 Jun 09. pii: S0344-0338(23)00291-1. [Epub ahead of print]248 154591
    Angiogenesis and prostate cancer: MicroRNAs comes into view.
    Jitendra Gupta, Nahla A Tayyib, Abduladheem Turki Jalil, Saif Hameed Hlail, Rahman S Zabibah, Ulug'bek N Vokhidov, Fahad Alsaikhan, Pushpamala Ramaiah, Lathamangeswari Chinnasamy, Mustafa M Kadhim.
      Angiogenesis, the formation of new blood vessels, is an important stage in the growth of cancer. Extracellular matrix, endothelial cells, and soluble substances must be carefully coordinated during the multistep procedure of angiogenesis. Inducers and inhibitors have been found to control pretty much every phase. In addition to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and angiogenesis have a critical role in the initiation and progression of prostate cancer. MicroRNA (miRNA) is endogenous, short, non-coding RNA molecules of almost 22 nucleotides play a role in regulating cellular processes and regulating several genes' expression. Through controlling endothelial migration, differentiation, death, and cell proliferation, miRNAs have a significant function in angiogenesis. A number of pathological and physiological processes, particularly prostate cancer's emergence, depend on the regulation of angiogenesis. Investigating the functions played with miRNAs in angiogenesis is crucial because it might result in the creation of novel prostate cancer therapies that entail regulating angiogenesis. The function of several miRNAs and its targeting genes engaged in cancer of the prostate angiogenesis will be reviewed in this review in light of the most recent developments. The potential clinical utility of miRNAs potentially a novel therapeutic targets will also be explored, as well as their capacity to control prostate cancer angiogenesis and the underlying mechanisms.
    Keywords:  Angiogenesis; MicroRNA; Prostate cancer; Vascular endothelial growth factor
    DOI:  https://doi.org/10.1016/j.prp.2023.154591
  4. Mol Biotechnol. 2023 Jun 19.
    MicroRNA-425: A Pivotal Regulator Participating in Tumorigenesis of Human Cancers.
    Pouriya Sameti, Mohammad Amini, Fatemeh Oroojalian, Yalda Baghay Esfandyari, Maryam Tohidast, Seyed Ali Rahmani, Shirin Azarbarzin, Ahad Mokhtarzadeh, Behzad Baradaran.
      MicroRNAs (miRNAs) are small single-stranded regulatory RNAs that are shown to be dysregulated in a wide array of human cancers. MiRNAs play critical roles in cancer progression and function as either oncogenes or tumor suppressors through modulating various target genes. Therefore, they possess great potential as diagnostic and therapeutic targets for cancer detection and treatment. In particular, recent studies have illustrated that miR-425 is also dysregulated in various human malignancies and plays a fundamental role in cancer initiation and progression. miR-425 has been reported to function as a dual-role miRNA participating in the regulation of cellular processes, including metastasis, invasion, and cell proliferation by modulating multiple signaling pathways, such as TGF-β, Wnt, and P13K/AKT pathways. Therefore, regarding recent researches showing the high therapeutic potential of miR-425, in this review, we have noted the impact of its dysregulation on signaling pathways and various aspects of tumorigenesis in a variety of human cancers.
    Keywords:  Cancer; MicroRNA-425; Signaling pathways
    DOI:  https://doi.org/10.1007/s12033-023-00756-5
  5. J Urol. 2023 Jun 19. 101097JU0000000000003587
    Urologic Oncology: Prostate Cancer.
    Samir S Taneja.
      
    DOI:  https://doi.org/10.1097/JU.0000000000003587
  6. Pathol Res Pract. 2023 Jun 17. pii: S0344-0338(23)00324-2. [Epub ahead of print]248 154624
    The potential role of miRNAs in the pathogenesis of cardiovascular diseases - A focus on signaling pathways interplay.
    Emad Gamil Khidr, Ahmed I Abulsoud, Ayman A Doghish, Hesham A El-Mahdy, Ahmed Ismail, Mohammed S Elballal, Omnia M Sarhan, Sherif S Abdel Mageed, Elsayed G E Elsakka, Samy Y Elkhawaga, Ahmed A El-Husseiny, Nourhan M Abdelmaksoud, Aya A El-Demerdash, Reem K Shahin, Heba M Midan, Mahmoud A Elrebehy, Osama A Mohammed, Logyna A Abulsoud, Ahmed S Doghish.
      For the past two decades since their discovery, scientists have linked microRNAs (miRNAs) to posttranscriptional regulation of gene expression in critical cardiac physiological and pathological processes. Multiple non-coding RNA species regulate cardiac muscle phenotypes to stabilize cardiac homeostasis. Different cardiac pathological conditions, including arrhythmia, myocardial infarction, and hypertrophy, are modulated by non-coding RNAs in response to stress or other pathological conditions. Besides, miRNAs are implicated in several modulatory signaling pathways of cardiovascular disorders including mitogen-activated protein kinase, nuclear factor kappa beta, protein kinase B (AKT), NOD-like receptor family pyrin domain-containing 3 (NLRP3), Jun N-terminal kinases (JNKs), Toll-like receptors (TLRs) and apoptotic protease-activating factor 1 (Apaf-1)/caspases. This review highlights the potential role of miRNAs as therapeutic targets and updates our understanding of their roles in the processes underlying pathogenic phenotypes of cardiac muscle.
    Keywords:  Cardiovascular diseases; MiRNA delivery vehicles; MiRNAs; Regulatory mechanisms; Therapeutic intervention
    DOI:  https://doi.org/10.1016/j.prp.2023.154624
  7. Neurologia (Engl Ed). 2023 Jul-Aug;38(6):pii: S2173-5808(23)00035-4. [Epub ahead of print]38(6): e41-e51
    The miRNA neuroinflammatory biomarkers in COVID-19 patients with different severity of illness.
    R Keikha, S M Hashemi-Shahri, A Jebali.
       INTRODUCTION: The expression of specific miRNAs and their mRNA targets are changed in infectious disease. The aim of this study was to analyze the expression of pro-neuroinflammatory miRNAs, anti-neuroinflammatory miRNAs, and their mRNA targets in the serum of COVID-19 patients with different grades.
    METHODS: COVID-19 patients with different grades were enrolled in this study and the expression of pro-neuroinflammatory miRNAs, anti-neuroinflammatory miRNAs, and their target mRNAs was analyzed by q-PCR.
    RESULTS: The relative expression of anti- neuroinflammatory miRNAs (mir-21, mir-124, and mir-146a) was decreased and the relative expression of their target mRNAs (IL-12p53, Stat3, and TRAF6) was increased. Also, the relative expression of pro-neuroinflammatory miRNAs (mir-326, mir-155, and mir-27b) was increased and the relative expression of their target mRNA (PPARS, SOCS1, and CEBPA) was decreased in COVID-19 patients with increase of disease grade. A negative significant correlation was seen between mir-21 and IL-12p53 mRNA, mir-124 and Stat3 mRNA, mir-146a and TRAF6 mRNA, mir-27b and PPARS mRNA, mir-155 and SOCS1 mRNA, and between mir-326 and CEBPA mRNA in COVID-19 patients (P<0.05).
    CONCLUSIONS: This study showed that the relative expression of anti- neuroinflammatory miRNAs was decreased and the relative expression of their targeted mRNAs was increased in COVID-19 patients from asymptomatic to critical illness. Also, this study showed that the relative expression of pro-neuroinflammatory miRNAs was increased and the relative expression of their targeted mRNA was decreased in COVID-19 patients from asymptomatic to critical illness.
    Keywords:  Anti-neuroinflamatorio; Anti-neuroinflammatory; COVID-19; Pro-neuroinflamatorio; Pro-neuroinflammatory; miARN; miRNAs
    DOI:  https://doi.org/10.1016/j.nrleng.2023.05.002
  8. Trends Microbiol. 2023 Jun 15. pii: S0966-842X(23)00163-4. [Epub ahead of print]
    Bacterial extracellular vesicles: an emerging avenue to tackle diseases.
    Junhua Xie, Freddy Haesebrouck, Lien Van Hoecke, Roosmarijn E Vandenbroucke.
      A growing body of research, especially in recent years, has shown that bacterial extracellular vesicles (bEVs) are one of the key underlying mechanisms behind the pathogenesis of various diseases like pulmonary fibrosis, sepsis, systemic bone loss, and Alzheimer's disease. Given these new insights, bEVs are proposed as an emerging vehicle that can be used as a diagnostic tool or to tackle diseases when used as a therapeutic target. To further boost the understanding of bEVs in health and disease we thoroughly discuss the contribution of bEVs in disease pathogenesis and the underlying mechanisms. In addition, we speculate on their potential as novel diagnostic biomarkers and how bEV-related mechanisms can be exploited as therapeutic targets.
    Keywords:  bacterial extracellular vesicles (bEVs); cytoplasmic membrane vesicles (CMVs); diagnostic biomarker; host–pathogen interaction; outer membrane vesicles (OMVs); pathogenesis; therapeutic target
    DOI:  https://doi.org/10.1016/j.tim.2023.05.010
  9. Int Urol Nephrol. 2023 Jun 20.
    The relationship between microRNAs and bladder cancer: are microRNAs useful to predict bladder cancer in suspicious patients?
    Mehmet Kaba, Necip Pirinççi, Murat Demir, Sultan Kaba, Serdar Oztuzcu, Samed Verep.
       PURPOSE: Recent studies indicate that circulating micro RNAs (miRNAs) are novel class of non-invasive biomarkers with diagnostic and prognostic information. We evaluated the miRNA expressions in bladder cancer (BC) and their associations with disease diagnosis.
    METHODS: We profiled the expressions of 379 miRNAs in the plasma samples from patients with non-muscle invasive bladder cancer (NMIBC) (n = 34) and non-malignant urological diseases as a control group (n = 32). Patients were evaluated regarding with age, miRNA expressions, by using descriptive statistics. miRNA expression in extracted RNA was quantified using the NanoString nCounter Digital Analyzer.
    RESULTS: The analysis of plasma miRNA levels in the marker identification cohort indicated that plasma (miR-1260a, let-7a-3p miR-196b-5p, miR-196a-5p, miR-99a-5p, miR-615-5p, miR-4301, miR-28-3p, miR-4538, miR-1233-3p, miR-4732-5p, miR-1913, miR-1280) levels were increased in NMIBC patients compared to control subjects. There were no significant differences other parameters studied between groups.
    CONCLUSIONS: The analysis of serum plasma miRNA (miR-1260a, let-7a-3p miR-196b-5p, miR-196a-5p, miR-99a-5p, miR-615-5p, miR-4301, miR-28-3p, miR-4538, miR-1233-3p, miR-4732-5p, miR-1913, miR-1280) levels could be useful plasma biomarkers for BC.
    Keywords:  Biomarker; Bladder cancer; miRNA
    DOI:  https://doi.org/10.1007/s11255-023-03666-2
  10. Angew Chem Int Ed Engl. 2023 Jun 19. e202305227
    An Extracellular miRNA-Responsive Artificial Receptor via Dynamic DNA Nano-assembly for Biomarker-Driven Therapy.
    Fang He, Meixia Wang, Jieyu Wang, Hong-Hui Wang, Zhou Nie.
      MicroRNAs (miRNAs) have emerged as promising diagnostic biomarkers and therapeutic targets in various diseases. However, there is currently a lack of molecular strategies that can effectively use disease-associated extracellular miRNAs as input signals to drive therapeutic functions. Herein, we present a modular and programmable miRNA-responsive chimeric DNA receptor (miRNA-CDR) capable of biomarker-driven therapy. By grafting a miRNA-responsive DNA nanodevice on a natural membrane receptor via aptamer anchoring, miRNA-CDR can sense extracellular miRNA levels and autonomously induce dimerization-mediated receptor activation via the complementary-mediated strand displacement reaction-induced dynamic DNA assembly. The sequence programmability of miRNA-CDR allows it to sense and respond to a user-defined miRNA with tunable sensitivity. Moreover, the miRNA-CDR is versatile and customizable to reprogram desirable signaling output via adapting a designated receptor, such as MET and FGFR1. Using a mouse model of drug-induced acute liver injury (DILI), we demonstrate the functionality of a de-signer miRNA-CDR in rewiring the recognition of the DILI-elevated miR-122 to promote MET signaling of hepatocytes for biomarker-driven in situ repair and liver function restoration. Our synthetic miRNA-CDR platform provides a novel molecular device enabling biomarker-driven therapeutic cellular response, potentially paving the way for improving the precision of cell therapy in regenerative medicine.
    Keywords:  Extracellular miRNA * Biomarker * DNA Nanotechnology * Artificial Receptors * Liver Injury
    DOI:  https://doi.org/10.1002/anie.202305227
This page is being maintained by Thomas Krichel. It was last updated on 2024‒11‒22 at 4:23.